{"id":1700,"date":"2022-02-22T00:00:00","date_gmt":"2022-02-22T05:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/"},"modified":"2023-06-14T19:55:11","modified_gmt":"2023-06-14T23:55:11","slug":"the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/","title":{"rendered":"The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes"},"content":{"rendered":"<p>Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP<sub>4i<\/sub>), while sulfonylureas may have a neutral or detrimental effect. We linked the Ontario subset of a prospective Canadian myelodysplastic syndromes (MDS) registry with provincial administrative databases. We assessed the impact of statin\/oral hypoglycemic medication exposure on overall survival (OS) using Cox regression analysis, controlling for comorbidities and sociodemographic factors. Five hundred thirty-three patients aged &#x2265; 66 years were included: 49.3% used statins, 18.9% used metformin, 9.0% used sulfonylureas, and 6.4% used DPP<sub>4i<\/sub>. Three hundred ninety-five patients were lower-risk based on the International Prognostic Scoring System. On univariate analysis, we identified a marginal improvement in OS in the lower-risk group using DPP<sub>4i<\/sub> (HR 0.98, 95% CI 0.95&#x2013;1.00, <em>P<\/em> = 0.05), while there was no impact on mortality for higher-risk DPP4i users (HR 1.03, CI 0.99&#x2013;1.07, <em>P<\/em> = 0.21). There was no mortality difference for statins (HR 1.00, CI 1.00&#x2013;1.01, <em>P<\/em> = 0.93), metformin (HR 1.00, CI 0.99&#x2013;1.01, <em>P<\/em> = 0.81), or sulfonylureas (HR 1.00, CI 0.99&#x2013;1.02, <em>P<\/em> = 0.43) in the entire cohort, as well as when stratified into lower\/higher-risk groups. On multivariable analysis in the lower-risk group, there was no association between DPP<sub>4i<\/sub> and OS (HR 0.98, CI 0.95&#x2013;1.00, <em>P<\/em> = 0.06). Prospective studies with larger cohorts of patients and longer follow-up are required to further study the impact of DPP<sub>4<\/sub>i in MDS.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while sulfonylureas may have a neutral or detrimental effect. We linked the Ontario subset of a prospective Canadian myelodysplastic syndromes (MDS) registry with provincial administrative databases. We assessed the impact of statin\/oral hypoglycemic medication exposure on overall survival (OS) using [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[],"migration-helper-qa-sample-set":[],"class_list":["post-1700","journal_article","type-journal_article","status-publish","hentry"],"acf":{"citation":"Brailovski E, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein RJ, Mozessohn L. <em>Ann Hematol. <\/em>2022; 101(5):1023-30. Epub 2022 Feb 22.","source_url":"https:\/\/doi.org\/10.1007\/s00277-022-04802-1","ices_scientist":[1193,1225,1318],"site":[6733],"research_program":[6741],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"16015AD4-2AEA-4DF8-992D-A8DAB3B4C176","sitecore_item_name":"The-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes","sitecore_field_values":"{\n  \"Title\": \"The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes\",\n  \"Short title\": \"The impact of oral hypoglycemics and\",\n  \"Summary\": \"This study assessed the impact of statin\/oral hypoglycemic medication exposure on overall survival (OS) using Cox regression analysis, controlling for comorbidities and sociodemographic factors.\",\n  \"Citation\": \"<p>Brailovski E, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Liu Y, Earle CC, Cheung MC, Mittmann N, Buckstein RJ, Mozessohn L. <em>Ann Hematol. <\/em>2022; 101(5):1023-30. Epub 2022 Feb 22. DOI: <a href=\"https:\/\/doi.org\/10.1007\/s00277-022-04802-1\" title=\"online ahead of print\">https:\/\/doi.org\/10.1007\/s00277-022-04802-1<\/a><\/p>\",\n  \"Abstract\": \"<p>Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP<sub>4i<\/sub>), while sulfonylureas may have a neutral or detrimental effect. We linked the Ontario subset of a prospective Canadian myelodysplastic syndromes (MDS) registry with provincial administrative databases. We assessed the impact of statin\/oral hypoglycemic medication exposure on overall survival (OS) using Cox regression analysis, controlling for comorbidities and sociodemographic factors. Five hundred thirty-three patients aged &ge; 66 years were included: 49.3% used statins, 18.9% used metformin, 9.0% used sulfonylureas, and 6.4% used DPP<sub>4i<\/sub>. Three hundred ninety-five patients were lower-risk based on the International Prognostic Scoring System. On univariate analysis, we identified a marginal improvement in OS in the lower-risk group using DPP<sub>4i<\/sub> (HR 0.98, 95% CI 0.95&ndash;1.00, <em>P<\/em> = 0.05), while there was no impact on mortality for higher-risk DPP4i users (HR 1.03, CI 0.99&ndash;1.07, <em>P<\/em> = 0.21). There was no mortality difference for statins (HR 1.00, CI 1.00&ndash;1.01, <em>P<\/em> = 0.93), metformin (HR 1.00, CI 0.99&ndash;1.01, <em>P<\/em> = 0.81), or sulfonylureas (HR 1.00, CI 0.99&ndash;1.02, <em>P<\/em> = 0.43) in the entire cohort, as well as when stratified into lower\/higher-risk groups. On multivariable analysis in the lower-risk group, there was no association between DPP<sub>4i<\/sub> and OS (HR 0.98, CI 0.95&ndash;1.00, <em>P<\/em> = 0.06). Prospective studies with larger cohorts of patients and longer follow-up are required to further study the impact of DPP<sub>4<\/sub>i in MDS.<\/p>\",\n  \"Research Programs\": \"{85DE96A6-4C96-40C7-8E6D-7597A0EB5F80}\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n  \"ICES Scientists\": \"{C61EC381-DBA1-4E07-8583-0E6F2F691360}|{B3A5A166-8F3C-43DC-8214-EFB653814F22}|{A14AA12C-3C52-4EAF-AD80-4F528976FA45}\",\n  \"Posted Date\": \"20220222T000000\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2022\/February\/The-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes<\/title>\n<meta name=\"description\" content=\"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes\" \/>\n<meta property=\"og:description\" content=\"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:55:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\\\/\",\"name\":\"ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2022-02-22T05:00:00+00:00\",\"dateModified\":\"2023-06-14T23:55:11+00:00\",\"description\":\"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes","description":"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes","og_description":"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:55:11+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/","name":"ICES | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2022-02-22T05:00:00+00:00","dateModified":"2023-06-14T23:55:11+00:00","description":"Observational studies suggest an anti-neoplastic effect associated with statins, metformin, and dipeptidyl peptidase-4 inhibitors (DPP4i), while","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/the-impact-of-oral-hypoglycemics-and-statins-on-outcomes-in-myelodysplastic-syndromes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/1700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1318"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1225"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1193"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=1700"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=1700"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=1700"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=1700"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=1700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}